Beam Therapeutics RSI
What is the RSI of Beam Therapeutics?
The RSI of Beam Therapeutics Inc. is 43.55
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with rsi similar to Beam Therapeutics
- Buru has RSI of 43.53
- Samkrg Pistons and Rings has RSI of 43.53
- New Leaf Ventures Inc has RSI of 43.54
- Scholar Rock Corp has RSI of 43.54
- East West has RSI of 43.54
- Yield Go has RSI of 43.54
- Beam Therapeutics has RSI of 43.55
- Coeur Mining Inc has RSI of 43.56
- Upland Resources has RSI of 43.56
- ArcPacific Resources has RSI of 43.56
- 1+1 Ag Inh O.N has RSI of 43.56
- Keyne Ltd has RSI of 43.56
- ZCCM Investments Plc has RSI of 43.56